Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05149638 · ClinicalTrials.gov registry record · NA
Updated Diagnostic Cortisol Values for Adrenal Insufficiency
A NA study of Adrenal Insufficiency, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05149638: Recruiting NA study of Adrenal Insufficiency, sponsored by Montefiore Medical Center.
NCT05149638 is a NA study of Adrenal Insufficiency that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 90 participants, below the 3,049-participant average among 5 other Adrenal Insufficiency trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05149638, a NA study of Adrenal Insufficiency, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the cortisol levels that most accurately diagnose a patient with adrenal insufficiency, a condition in which cortisol levels are too low for daily living.
Primary Outcome
To accurately re-define the cortisol threshold to diagnose adrenal insufficiency (AI) with cosyntropin stimulation test (CST) using the Alinity, monoclonal antibody, cortisol assay. The cortisol threshold for the diagnosis of AI using the Alinity assay is 18 ug/dL. Results from the CST assay will be summarized by study arm/group to determine a new cut-point for patients with suspected primary or central AI.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Cosyntropin stimulation test
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-02-03 |
| Est. Completion | 2027-12-01 |
| Phase | NA |
What NCT05149638 shows while recruiting
NCT05149638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 3,049-participant average among 5 other Adrenal Insufficiency trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Adrenal Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which Cosyntropin stimulation test is the first listed.
NCT05149638 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05149638 about?
NCT05149638 is a clinical study titled "Updated Diagnostic Cortisol Values for Adrenal Insufficiency". The purpose of this study is to determine the cortisol levels that most accurately diagnose a patient with adrenal insufficiency, a condition in which cortisol levels are too low for daily living.
What is the current status of trial NCT05149638?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2022-02-03. Estimated completion is 2027-12-01.
What conditions does trial NCT05149638 study?
This clinical trial studies the following conditions: Adrenal Insufficiency.
What interventions are being tested in trial NCT05149638?
The interventions under investigation include: Cosyntropin stimulation test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05149638?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05149638 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenal Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
RECRUITING
-
Evaluation of Children With Endocrine and Metabolic-Related Conditions
RECRUITING
-
Cortisol Response to Moderate and Deep Sedation in Children
COMPLETED
-
Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis
COMPLETED
-
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI